Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 13

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 13
---
 arts degree in political science and a bachelor of law degree from the University of Windsor. We believe our management team is well positioned to take advantage of the growing set of investment opportunities focused on the pharmaceutical industry, and that our extensive existing relationships with portfolio companies along with our ongoing efforts to identify investment opportunities will allow us to generate an attractive transaction for our shareholders Our Sponsor Drugs Made In America Acquisition Corp. is an affiliate of our sponsor, Drugs Made In America Acquisition LLC. Formed in April 2024, the sponsor is a U.S. -basedlimited liability company formed for the purpose of acting as the sponsor in connection with this offering and the sponsor conducts no other business. The managing 2 member of the sponsor is Lynn Stockwell, our Chief Executive Officer and Executive Chair. Ms. Stockwell controls the management of our sponsor, including the exercise of voting and investment discretion over the securities of our company held by our sponsor. Ms. Stockwell owns membership interests in our sponsor, which represent approximately [___]% of the economic interests in our sponsor. As of the date hereof, other than Ms. Stockwell, no other person has a direct or indirect material interest in our sponsor. Additionally, subject to each non -managingsponsor investor purchasing, through the sponsor, the private units allocated to it in connection with the closing of this offering, the sponsor will issue membership interests at a nominal purchase price to the non -managingsponsor investors reflecting interests in an aggregate of 666,667 founder shares held by the sponsor. Non -managingsponsor investors will have no right to control the sponsor or participate in any decision regarding the disposal of any security held by the sponsor, or otherwise. See “ Principal Shareholders — Sponsor Ownership.” Business Strategy Our acquisition and value creation strategy is to identify, acquire and, after our initial business combination, further accelerate the growth of a company in the pharmaceutical industry. We believe our management team’s knowledge, decades of experience and relationships across this industry can effect a positive transformation or augmentation of an existing business model through implementing proven business strategies within the pharmaceutical industry. Our team is well positioned to originate attractive investment opportunities and has a history of executing various business transactions in multiple geographies and under varying economic and financial market conditions. Once we have completed our initial public offering, our team will identify potential acquisition targets by leveraging existing relationships in combination with the market research data that aligns with the company’s strategic goals and priorities. Market size, growth potential, competition, and barriers to entry are all essential factors to consider